Preparation and structure-activity relationships of novel asterriquinone derivatives

Chemical and Pharmaceutical Bulletin

Volumn 46, Issue 8, 1998, Pages 1325-1329

  Kaji, Akira ^a   Kimura, Kengo ^a   Teranishi, Masanori ^a   Kiriyama, Noriki ^a   Nomura, Masaaki ^b   Miyamoto, Ken Ichi ^b  

^a HOKURIKU UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Asterriquinone; Cytotoxicity; Mouse leukemia P388 cell; Partial deacetylation; Structure activity relationship

Indexed keywords

ANTINEOPLASTIC AGENT; ASTERRIQUINONE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASPERGILLUS TERREUS; CHEMICAL MODIFICATION; CYTOTOXICITY; DERIVATIZATION; DRUG SYNTHESIS; LEUKEMIA CELL; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 0031756308     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.46.1325     Document Type: Article

References (25)

1. A part of this work was published as a preliminary communication: Kaji A., Kimura K., Iwata T., Kiriyama N., Chem. Pharm. Bull., 43, 1818-1820 (1995).
2. a) Yamamoto Y., Nishimura K., Kiriyama N., Chem. Pharm. Bull., 24, 1853-1859 (1976);
3. b) Kaji A., Iwata T., Kiriyama N., Wakusawa S., Miyamoto K., ibid., 42, 1682-1684 (1994);
4. Arai K., Shimizu S., Taguchi Y., Yamamoto Y., ibid., 29, 991-999 (1981).
5. a) Yamamoto Y., Kiriyama N., Shimizu S., Koshimura S., Gann, Jpn. J. Cancer Res., 67, 623-624 (1976);
6. b) Shimizu S., Yamamoto Y., Koshimura S., Chem. Pharm. Bull, 30, 1896-1899 (1982);
7. Shimizu S., Yamamoto Y., Inagaki J., Koshimura S., Gann, Jpn. J. Cancer Res., 73, 642-648 (1982).
8. Kaji A., Saito R., Nomura M., Miyamoto K., Kiriyama N., Anticancer Res., 17, 3675-3680 (1997).
9. Kaji A., Iwata T., Kiriyama N., Nomura M., Miyamoto K., J Antibiot., 51, 235-238 (1998).
10. a) Fierz-David H. E., Blangey L., Streiff H., Helv. Chim. Acta, 29, 1718-1764 (1946);
11. b) Schill G., Henschel R., Justus Liebigs Ann. Chem., 731, 113-119 (1970);
12. Cameron D. W., Giles R. G. F., J. Chem. Soc., 1968, 1461-1464.
13. a) Farfán N., Ortega E., Contreras R., J. Heterocycl. Chem., 23, 1609-1612 (1986);
14. b) Anslow W. K., Raistrick H.,V. Chem. Soc., 1939, 1446-1457;
15. Kitanaka S., Takido M., Yakugaku Zasshi, 106, 302-306 (1986).
16. a) Tsuda Y., Nunozawa T., Nitta K., Yamamoto Y., Chem. Pharm. Bull., 28, 920-925 (1980);
17. b) Moore R. E., Singh H., Scheuer P. J., J. Org. Chem., 31, 3645-3650 (1966);
18. Jones R. G., Shonle H. A., J. Am. Chem. Soc., 67, 1034-1035 (1945);
19. Anslow W. K., Ashley J. N., Raistrick H., J. Chem. Soc., 1938, 439-442.
20. Besl H., Bresinsky A., Geigenmüller G., Herrmann R., Kilpert C., Steglich W., Justus Liebigs Ann. Chem., 1989, 803-810.
21. Carmichael J., DeGraff W. G., Gazdar A. F., Minna J. D., Mitchell J. B., Cancer Res., 47, 936-942 (1987).
22. a) Calabresi P., Chabner B. A., "Pharmacologic Basis of Therapeutics," ed. by Gilman A. G., Rall T. W., Nies A. S., Taylor P., Pergamon Press, New York, 1990, pp. 1202-1263;
23. b) Meijer C., Mulder N. H., Timmer-Bosscha H., Zijlatra J. G., De Vries E. G. E., Cancer Res., 47, 4613-4617 (1987).
24. 2b) the total amount of 1a and 3a per 12 1 medium were 730 mg and 36 mg, respectively. In this study, using modified malt extract medium [malt extract, 20g; glucose, 20 g; polypepton Y® (Wako Pure Chemical Industries, Ltd.), 8g; tap water 11], 1a (1063mg) and 3a (155 mg) were obtained in good yield.
25. Arai K., Ph. D. Thesis, Kyoto University, Kyoto, Japan, 1984.